» Articles » PMID: 17337137

Nasal Administration of an Angiotensin Antagonist in the Rat Model: Effect of Bioadhesive Formulations on the Distribution of Drugs to the Systemic and Central Nervous Systems

Overview
Journal Int J Pharm
Specialties Chemistry
Pharmacology
Date 2007 Mar 6
PMID 17337137
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The effect of bioadhesive formulations on the direct transport of an angiotensin antagonist drug ((14)C-GR138950) from the nasal cavity to the central nervous system was evaluated in a rat model. Three different bioadhesive polymer formulations (3% pectin LM-5, 1.0% pectin LM-12 and 0.5% chitosan G210) containing the drug were administered nasally to rats by inserting a dosing cannula 7mm into the nasal cavity after which the plasma and brain tissue levels were measured. It was found that the polymer formulations provided significantly higher plasma levels and significantly lower brain tissue levels of drug than a control, in the form of a simple drug solution. Changing the depth of insertion of the cannula from 7 to 15mm, in order to reach the olfactory region in the nasal cavity significantly decreased plasma levels and significantly increased brain tissue levels of drug for the two formulations studied (1.0% pectin LM-12 and a simple drug solution). There was no significant difference between the drug availability for the bioadhesive formulation and the control in the brain when the longer cannula was used for administration. It is suggested that the conventional rat model is not suitable for evaluation of the effects of bioadhesive formulations in nose-to-brain delivery.

Citing Articles

In-depth Mechanism, Challenges, and Opportunities of Delivering Therapeutics in Brain Using Intranasal Route.

Ghosh A, Majie A, Karmakar V, Chatterjee K, Chakraborty S, Pandey M AAPS PharmSciTech. 2024; 25(5):96.

PMID: 38710855 DOI: 10.1208/s12249-024-02810-0.


Intranasal application of PACAP and β-cyclodextrin before the "critical period of proestrous stage" can block ovulation.

Heinzlmann A, Olah M, Koves K Biol Futur. 2021; 70(1):62-70.

PMID: 34554429 DOI: 10.1556/019.70.2019.08.


Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies.

Li G, Bonamici N, Dey M, Lesniak M, Balyasnikova I Expert Opin Drug Deliv. 2017; 15(2):163-172.

PMID: 28895435 PMC: 5847369. DOI: 10.1080/17425247.2018.1378642.


Intranasal delivery of N-terminal modified leptin-pluronic conjugate for treatment of obesity.

Yuan D, Yi X, Zhao Y, Poon C, Bullock K, Hansen K J Control Release. 2017; 263:172-184.

PMID: 28344017 PMC: 5603367. DOI: 10.1016/j.jconrel.2017.03.029.


Low-dose oxytocin delivered intranasally with Breath Powered device affects social-cognitive behavior: a randomized four-way crossover trial with nasal cavity dimension assessment.

Quintana D, Westlye L, Rustan O, Tesli N, Poppy C, Smevik H Transl Psychiatry. 2015; 5:e602.

PMID: 26171983 PMC: 5068727. DOI: 10.1038/tp.2015.93.